Brian K Meyer, J Vaccines Vaccin 2014, 5:5
http://dx.doi.org/10.4172/2157-7560.S1.020

OMICS Group Conferences
Accelerating Scientific Discovery

4th International Conference on
Vaccines & Vaccination
September 24-26, 2014 Valencia Convention Centre, Spain

Evaluation of ZOSTAVAX® via the intradermal route using the MicronJet™

Brian K Meyer[1], **Chan Beals**[1], **Yotam Levin**[2] and **Robert K Evans**[1]
[1]Merck & Co., USA
[2]Nanopass Technologies Ltd., Israel

Here we report the results of intradermal vaccination studies that were performed with an attenuated virus (varicella; ZOSTAVAX®). Intradermal vaccination using the MicronJet™ by Nanopass Technologies was compared to the current route of administration (subcutaneous). It was demonstrated with ZOSTAVAX® that doses of 1/3rd and 1/10th, the full dose elicited both antibody and T-cell responses that were equivalent to a full dose delivered subcutaneously. A full dose of ZOSTAVAX® administered intradermally resulted in a higher overall antibody titer when compared to the subcutaneous route.

Biography

Brian K Meyer is a Principal Scientist in Bioprocess Research and Development, Merck Research Laboratories. He completed his PhD at The Pennsylvania State University. He has held various positions at Merck, both in the research and manufacturing divisions.

brian_meyer@merck.com